Myriad Genetics (MYGN +3.3%) moves up this morning after Goldman upgraded shares to Buy with a...


Myriad Genetics (MYGN +3.3%) moves up this morning after Goldman upgraded shares to Buy with a price target of $29. The firm says reimbursement concerns are overdone, plus the stock should gain added traction from the strength of its pipeline and a potential new dividend.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs